NCYT.L Stock - Novacyt S.A.
Unlock GoAI Insights for NCYT.L
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Free 14-day trial • No credit card required
Premium members get real-time SMS alerts
Financial Statements
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $19.63M | $11.58M | $21.04M | $95.78M | $277.20M |
| Gross Profit | $32.07M | $3.73M | $5.75M | $29.68M | $211.13M |
| Gross Margin | 163.4% | 32.2% | 27.3% | 31.0% | 76.2% |
| Operating Income | $-37,343,000 | $-29,516,000 | $-16,602,000 | $-1,367,000 | $167.44M |
| Net Income | $-41,758,000 | $-28,292,000 | $-22,201,000 | $-9,728,000 | $132.42M |
| Net Margin | -212.7% | -244.3% | -105.5% | -10.2% | 47.8% |
| EPS | $-0.59 | $-0.40 | $-0.31 | $-0.14 | $1.94 |
Novacyt S.A., together with its subsidiaries, engages in the development, manufacture, contract design, and commercialization of diagnostic products for cancer and infectious diseases in the United Kingdom, rest of Europe, the United States, the Asia Pacific, the Middle East, and Africa. It operates through Primer Design, Lab21 Products, and IT-IS International. The Primer Design segment designs, manufactures, and markets molecular real-time qPCR testing devices and reagents in the areas of infectious diseases. The Lab21 Products segment develops, manufactures, and distributes a range of protein-based infectious disease in-vitro diagnostic device (IVD) products. The IT-IS International segment develops and manufactures PCR devices for the life sciences and food testing industry. It serves hospitals and corporates. The company was incorporated in 2006 and is based in Vélizy-Villacoublay, France.
Visit WebsiteEarnings History & Surprises
NCYT.LEPS Surprise History
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q3 2025 | Sep 30, 2025 | — | — | — | — |
Q2 2025 | Jun 26, 2025 | — | — | — | — |
Q2 2025 | Apr 30, 2025 | — | — | — | — |
Q1 2025 | Jan 30, 2025 | — | $-0.28 | — | — |
Q3 2024 | Sep 26, 2024 | — | — | — | — |
Q3 2024 | Jul 25, 2024 | — | $-0.21 | — | — |
Q2 2024 | May 30, 2024 | — | — | — | — |
Q4 2023 | Dec 31, 2023 | — | $-0.25 | — | — |
Q3 2023 | Sep 28, 2023 | — | — | — | — |
Q2 2023 | Jun 30, 2023 | — | $-0.06 | — | — |
Q1 2023 | Mar 31, 2023 | — | $-0.06 | — | — |
Q4 2022 | Dec 31, 2022 | — | $-0.12 | — | — |
Q3 2022 | Sep 30, 2022 | — | $-0.12 | — | — |
Q2 2022 | Jun 30, 2022 | — | $-0.13 | — | — |
Q2 2022 | Apr 28, 2022 | — | — | — | — |
Q4 2021 | Dec 31, 2021 | — | $0.03 | — | — |
Q3 2021 | Sep 27, 2021 | — | $-0.00 | — | — |
Q3 2021 | Sep 27, 2021 | — | $-0.00 | — | — |
Q2 2021 | Jun 30, 2021 | — | $-0.15 | — | — |
Q3 2020 | Sep 17, 2020 | — | $0.55 | — | — |
Latest News
Frequently Asked Questions about NCYT.L
What is NCYT.L's current stock price?
What is the analyst price target for NCYT.L?
What sector is Novacyt S.A. in?
What is NCYT.L's market cap?
Does NCYT.L pay dividends?
Similar Stocks
Healthcare SectorExplore stocks similar to NCYT.L for comparison